Effect of direct‐acting antivirals on platelet‐associated immunoglobulin G and thrombocytopenia in hepatitis C virus‐related chronic liver disease

Abstract Sera of 658 patients who had completed treatment for pediatric malignancy were analyzed by a second-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay test to assess the prevalence of hepatitis C virus (HCV)-seropositivity. All HCV-seropositive patients underwent detailed clinical, laboratory, virologic, and histologic study to analyze the course of HCV infection. One hundred seventeen of the 658 patients (17.8%) were positive for HCV infection markers. Among the 117 anti-HCV+ patients, 41 (35%) were also positive for markers of hepatitis B virus infection with or without delta virus infection markers, 91 (77.8%) had previously received blood product transfusions, and 25 (21.4%) showed a normal alanine aminotransferase (ALT) level during the last 5-year follow-up (11 of them never had abnormal ALT levels). The remaining 92 patients showed ALT levels higher than the upper limit of normal range. Eighty-one of 117 (70%) anti-HCV+ patients were HCV-RNA+, with genotype 1b being present in most patients (54%). In univariate analysis, no risk factor for chronic liver disease was statistically significant. In this study, the prevalence of HCV infection was high in patients who were treated for a childhood malignancy. In about 20% of anti-HCV+ patients, routes other than blood transfusions are to be considered in the epidemiology of HCV infection. After a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure.

Download Full-text

Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals

Annals of Pharmacotherapy ◽

10.1177/1060028020964117 ◽

2020 ◽

pp. 106002802096411

Author(s):

Anthony J. Gentene ◽

Allison M. Bell ◽

Alicia Pence ◽

Kelly Thomas ◽

Collin Jakubecz ◽

...

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Sustained Virologic Response ◽

Disease Patient ◽

Virologic Response ◽

Great Success ◽

Direct Acting Antivirals ◽

Inpatient Mortality ◽

Direct Acting

Background: Direct-acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) have resulted in great success through high attainment of sustained virologic response (SVR). Risk factors for DAA treatment failure are important to identify because of worsened outcomes with failure and high treatment cost. Objective: We sought to identify whether hospitalization during treatment affects SVR. The primary outcome was the difference in SVR at 12 weeks after treatment Methods: This multicenter, single health system retrospective cohort review compared achievement of SVR between patients hospitalized during DAA treatment for HCV with those not hospitalized during treatment. Results: Patients in the hospitalized cohort (n = 94) had more severe disease at baseline than nonhospitalized patients (n = 167) as indicated through higher Model for End-Stage Liver Disease (MELD) scores, Fibrosis-4 scores, and imaging-suggested or biopsy-confirmed cirrhosis. Patients hospitalized during treatment had lower SVR rates compared with those not hospitalized (87.2% vs 95.2%; P = 0.043) but failed to reach significance when inpatient mortality was excluded on secondary analysis (91.1% vs 95.2%; P = 0.195). Patients who were hospitalized and did not achieve SVR had higher MELD scores, were more likely to have intensive care unit stay, and had longer hospital stay compared with those who achieved SVR. Of 94 patients, 93 provided home supply of DAAs during hospitalization. Conclusion and Relevance: Patients hospitalized during DAA treatment for HCV had reduced rates of SVR. This reduced SVR rate may be driven by inpatient mortality and severity of liver disease. Patient education to bring home supply of medication for use during admission is an effective intervention.

Download Full-text

Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease?

Annals of Hepatology ◽

10.1016/s1665-2681(19)32072-1 ◽

2005 ◽

Vol 4 (2) ◽

pp. 100-106 ◽

Cited By ~ 22

Author(s):

Giovanni Raimondo ◽

Gaia Cacciamo ◽

Carlo Saitta

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Chronic Liver Disease ◽

Chronic Liver ◽

B Virus

Download Full-text

Prevalence of hepatitis C virus infection in the household contacts of patients with HCV-related chronic liver disease

Infection ◽

10.1007/bf01716699 ◽

1994 ◽

Vol 22 (3) ◽

pp. 183-186 ◽

Cited By ~ 13

Author(s):

M. Coltorti ◽

Nicola Caporaso ◽

Filomena Morisco ◽

Rosalba Suozzo ◽

M. Romano ◽

...

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Liver Disease ◽

Chronic Liver ◽

Hepatitis C Virus Infection ◽

Household Contacts

Download Full-text

Cost-effectiveness analyses of anti-hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan

Hepatology Research ◽

10.1111/hepr.13053 ◽

2018 ◽

Vol 48 (7) ◽

pp. 509-520 ◽

Cited By ~ 4

Author(s):

Terumi Kaishima ◽

Tomoyuki Akita ◽

Masayuki Ohisa ◽

Kazuaki Sakamune ◽

Akemi Kurisu ◽

...

Keyword(s):

Quality Of Life ◽

Hepatitis C Virus ◽

Liver Disease ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Liver Disease ◽

Chronic Liver ◽

Hiroshima Prefecture

Download Full-text

Burden of Liver Cirrhosis in Portugal between 2010 and 2017

GE Portuguese Journal of Gastroenterology ◽

10.1159/000510729 ◽

2020 ◽

pp. 1-9

Author(s):

João Manuel Silva ◽

Mário Jorge Silva ◽

Filipe Calinas ◽

Paulo Jorge Nogueira

Keyword(s):

Liver Cirrhosis ◽

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Liver Disease ◽

Hospital Admissions ◽

Chronic Liver ◽

Years Of Life Lost ◽

Hepatitis C Virus Infection

Introduction: Liver cirrhosis is a prevalent disease in Portugal. Recent changes in alcohol consumption, as well as the wide use of direct-acting antivirals for hepatitis C since 2015, may be contributing to changes in the national burden of liver cirrhosis in the last few years. Objectives: We aim to characterize the burden of cirrhosis in Portugal between 2010 and 2017. Patients and Methods: We analyzed all hospital admission episodes due to cirrhosis in Portugal Mainland between 2010 and 2017, registered in the national Diagnosis-Related Group database, according to etiology of cirrhosis. We also analyzed data on mortality and potential years of life lost from liver cirrhosis and chronic liver disease, retrieved from Statistics Portugal (National Institute for Statistics). Results: Between 2010 and 2017, a total of 51,438 admissions for liver cirrhosis occurred in Portugal. The annual number of admissions decreased (p = 0.044) during the analyzed period. The most frequent cause of cirrhosis was alcoholic liver disease, present in 78.9% of all admissions (n = 40,595), followed by chronic hepatitis C virus infection, present in 11.3% (n = 5,823). A male predominance was identified in the admissions for every analyzed cause of cirrhosis. Annual admissions for alcoholic cirrhosis remained stable (p = 0.075) during the 8-year period. The same stable tendency was observed in the number of admissions for cirrhosis caused by hepatitis C virus (p = 0.861) and alcohol plus hepatitis C virus infection (p = 0.082), although these admissions for hepatitis C-related cirrhosis increased until 2014–2015 and steadily decreased thereafter. Annual deaths due to liver cirrhosis and chronic liver disease decreased from 1,357 in 2010 to 1,038 in 2017 (p = 0.002). The number of potential years of life lost decreased as well in the period (p = 0.001). Conclusion: The burden of cirrhosis, evaluated by hospital admissions, mortality, and potential years of life lost, decreased in Portugal between 2010 and 2017.

Download Full-text